Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684827 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00684827 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 32 participants.
The verdict
NCT00684827, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.
Interventions
- DRUG Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
- DRUG Racemic Albuterol followed by levalbuterol HFA MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00684827
The ClinicalTrials.gov registry entry for NCT00684827 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI is the first listed.
NCT00684827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00684827 about?
NCT00684827 is a clinical study titled "A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma". The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.
What is the current status of trial NCT00684827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2002-10. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00684827?
The interventions under investigation include: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI (DRUG), Racemic Albuterol followed by levalbuterol HFA MDI (DRUG).
Who is sponsoring clinical trial NCT00684827?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.